Castle Biosciences (CSTL) Total Liabilities (2018 - 2026)

Castle Biosciences has disclosed Total Liabilities across 9 years of filings, most recently posting $91.1 million for Q2 2026.

• In Q2 2026, Total Liabilities rose 2.01% year-over-year to $91.1 million; the TTM figure through Jun 2026 stood at $91.1 million (up 2.01% YoY), while the FY2025 annual figure was $107.7 million, up 42.82% from the prior year.
• Total Liabilities came in at $91.1 million for Q2 2026 at Castle Biosciences, up from $86.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $107.7 million in Q4 2025 to a low of $36.7 million in Q2 2022.
• Average Total Liabilities over 5 years is $65.5 million, with a median of $61.7 million recorded in 2023.
• Year-over-year, Total Liabilities jumped 151.21% in 2022 and decreased 11.36% in 2023.
• Over 5 years, Total Liabilities stood at $48.2 million in 2022, then increased by 28.83% to $62.1 million in 2023, then increased by 21.47% to $75.4 million in 2024, then soared by 42.82% to $107.7 million in 2025, then fell by 15.36% to $91.1 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $91.1 million in Q2 2026, $86.4 million in Q1 2026, and $107.7 million in Q4 2025.